Stem cells may fix COPD lungs – early study launched

NCT ID NCT06755008

Recruiting now Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether induced pluripotent stem cells (iPS cells) can repair damaged lung tissue from people with COPD. Researchers will take small lung samples from 50 participants (COPD patients, smokers without COPD, and non-smokers) during a routine bronchoscopy. In the lab, they will grow the tissue and see if adding iPS cells helps it heal faster. This is a basic science study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: induced pluripotent stem cells (iPS cells)
What this could lead to: If successful, this could point toward a cell-based therapy to repair lung damage in COPD patients.
What could go wrong: This is a very early, small lab-based study (50 people) looking at cells in a dish, not a treatment in humans. It may not lead to any real-world therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE

Contacts and locations

Locations

University Hospital of Montpellier, Arnaud de Villeneuve Hospital
RECRUITING

Montpellier, Hérault, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.